Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Size: px
Start display at page:

Download "Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma"

Transcription

1 HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma Craig Moskowitz Memorial Sloan-Kettering Cancer Center, and Weil Medical College of Cornell University, New York, NY The majority of patients with Hodgkin lymphoma are cured with frontline therapy; however, 10% to 15% with early-stage disease and 20% to 30% with advanced stage require second-line therapy that includes a potentially curative transplant, of which an additional 50% to 55% are cured. Those with multiply relapsed disease traditionally would receive novel agents on a clinical trial or combination chemotherapy as a potential bridge to an allogeneic stem cell transplant. This treatment paradigm has changed with the availability of brentuximab vedotin, an antibody drug conjugate used pre- and post-asct, as well as for palliation. With the availability of the checkpoint inhibitors, nivolumab and pembrolizumab, there will be another shift in treatment, with these agents being used for palliation and potentially replacing allogeneic stem cell transplantation in certain patient populations. Finally, up-front management is also changing and this will have an impact on how patients in the relapsed and refractory setting will be treated. Learning Objectives Understanding risk factors that predict outcome in relapsed and refractory Hodgkin lymphoma Understanding how to incorporate brentuximab vedotin and the checkpoint inhibitors into the treatment paradigm This chapter will focus on 5 aspects that are critical in the treatment of patients with relapsed and refractory transplant-eligible Hodgkin lymphoma (HL): the role of pre allogeneic stem cell transplant (ASCT) positron emission tomography (PET) imaging, incorporation of brentuximab vedotin (BV) into salvage therapy, patients eligible for post- ASCT consolidation, use of checkpoint inhibitors (CPI), and the future role of allogeneic hematopoietic cell transplantation (allo-hct) in the management of this disease. The treatment algorithm for the primary management of HL has evolved over the past 3 decades, leading to a change in the patient populations requiring aggressive second-line therapy. The optimal chemotherapy for advanced stage HL (ASHL) can be endlessly debated, but progression-free survival (PFS) has improved by 15% in the past 2 decades. 1,2 For early-stage HL (ESHL), PFS is unchanged at close to 90% despite decreasing the number of cycles of doxorubicin (Adriamycin)-Bleomycin-Vinblastine-Dacarbazine administered and reducing the dose and size of radiation therapy fields. 3 From 1990 to 2010, relapsed/refractory (rel/ref) HL patients that underwent consultation for autologous stem cell transplantation (ASCT) had received either full-course chemotherapy or combined modality therapy (CMT) as frontline treatment; currently there exists a substantial proportion of patients who received short-course chemotherapy alone or were enrolled in PET-adapted advanced-stage studies, of which the results were not successful. The presumed response that all rel/ref HL patients must receive salvage therapy (ST) followed by high-dose chemo-radiotherapy (HDT)/ASCT, and if chemosensitive disease is achieved, may need to be addressed. In addition, when this second-line approach fails, do all patients require a consultation for a reducedintensity conditioning (RIC) allo-hct in the era of excellent new agents, where palliation for prolonged periods of time is now standard and expected? These issues will be discussed in this chapter as well as at the ASH meeting; there are many historical reviews cataloging various salvage regimens and transplant conditioning regimens to which the reader can be referred and these will not be discussed further. 4,5 What are the current patient populations requiring second-line therapy? Currently any patient with adequate end-organ function and performance status, and who are,75 years old, are treated aggressively with second-line therapy with the intent for high-dose therapy (HDT)/ASCT to follow. These patient populations include: early or advanced stage, relapsed and primary refractory HL treated with full chemotherapy; and early-stage HL treated with combined modality therapy with disease either insid,e the radiation field or advanced-stage disease at the time of ST. As therapy for ESHL evolves it is currently unclear whether patients treated with shortcourse chemotherapy alone (3-4 cycles of doxorubicin [Adriamycin]- Bleomycin-Vinblastine-Dacarbazine), with early stage disease at the time of ST, require HDT/ASCT. For example, in the RAPID study, 6 many patients with relapsed disease received radiation therapy alone for salvage. Because so few patients with ESHL relapse, it will be difficult to assess the need for HDT in this specific patient population in a randomized controlled clinical trial. Pre-ASCT FDG-PET HDT/ASCT is standard of care for relapsed or primary refractory HL if chemosensitive disease to ST is confirmed, leading to a cure in approximately 50% of the transplanted patients. 7 It is very clear that the cure rate ranges from 25% to 75% depending on prognostic Conflict-of-interest disclosure: The author has received research funding from Seattle Genetics and Merck, and has consulted for Seattle Genetics, Merck, and BMS. Off-label drug use: None disclosed. Hematology

2 Figure 1. All transplanted patients, functional imaging negative vs positive pretransplant treated MSKCC, factors Response to ST, whether complete or partial, is by far the most important predictor of outcome in this setting. In 2010, our group determined that chemosensitive disease should be defined by the pre-transplant 18F-fluorodeoxyglucose (FDG)-PET result. 11 These results have been expanded and updated. A negative scan after platinumbased therapy leads to a 10-year overall survival (OS) rate of 75%. For patients with documented improvement on computed tomography (CT), but with a persistent PET-avidity, only 30% are cured (Figure 1). There are now many clinical trials suggesting that a negative pretransplant FDG-PET has prognostic value, 12,13 and this has been confirmed in a recently published meta-analysis review. 14,15 Idefine the post ST PET scan as an interim evaluation; remission is defined 90 to 100 days post-asct. Based on this premise, nuclear medicine reports need to be interpreted using the 5-point (Deauville) criteria, with scores 4 and 5 defined as a positive scan. 16 How many attempts should be made to achieve the goal of a negative scan? There is no correct answer, but it is reasonable to attempt 2 distinct ST programs for advance-stage disease. For stage I/II disease that can be encompassed into a reasonable radiation therapy field, this treatment should also be attempted to achieve a complete response (CR) before ASCT. There is evidence that patients requiring more than one regimen to achieve PET negativity have a nearly similar outcome compared with those who receive only one ST program. 17 Complicating that matter further, not all patients with a post ST PET negative, complete response are cured and the contrary is also true; as much as 40% of patients transplanted with PET-avid disease achieve long-term PFS rate. Patients with nodal-only disease have a superior outcome to that of patients with stage IV disease. For example, patients with nodal-only disease in remission at the time of ASCT have an 80% to 90% cure rate compared with 55% to 65% for patients with extranodal disease Summary/Recommendation: A negative pre-asct PET scan is critical if a favorable outcome with HDT/ASCT is to be achieved and should be required for this treatment to continue to be the standard of care; however, since as much as 40% of patients with a positive scan are cured, ASCT should not be withheld, especially for patients without extranodal involvement. Primary refractory HL. Investigators consider primary refractory HL unfavorable. Most series present data only for the transplanted cohort; there is a lack of intent-to-treat second-line data. Compounding the problem, analyses for primary refractory and relapsed patients are often combined, making it somewhat difficult to tease out the data. If one summarizes the information,,50% of patients with primary refractory HL are progression-free. 21 We have recently reported on a large intent-to-treat primary refractory HL dataset compiled from patients treated on prospective ST studies at MSKCC. The median 5-year EFS for these 192 patients was 54%. The same 2 risk factors predicted for outcome: stage IV disease before ST and a positive PET scan after ST. A risk stratification model was created assigning 1 point for each factor. The 5-year EFS was 84% for patients with 0 risk factors, 54% with 1 risk factor, and only 28% for patients with both. Another large relapsed/refractory series was recently reported at ASH in 2015 by Broeckelmann et al. Multivariable analysis once again identified stage IV, primary refractory disease, and inadequate response to salvage chemotherapy as significant independent risk factors for PFS. 22 The incorporation of BV into ST Two to 3 cycles of ST is the standard of care and administered to all patients as part of a curative second-line strategy. Historically, the goal of ST was to achieve chemosensitive disease before curative HDT/ASCT. As stated before, in 2016 the goal of ST is far more significant and a CR or PET-negative response should be the objective. In fact, with the availability of new agents, patients who have a persistently positive scan after.1 ST may be not appropriate candidates for ASCT. Practitioners need to decide whether this patient population should receive novel drugs as part of a chronic or noncurative strategy vs a highly aggressive allo-hct program. 23 Prospective, randomized trials comparing different salvage regimens in HL are not available. If one summarizes the data for platinum and nonplatinum-containing ST regimens, a reasonable benchmark is a 50% to 60% CR or PET-negative rate with standard ST, but can this number be improved? 24 BV is an antibody-drug conjugate (ADC) composed of a CD30-directed monoclonal antibody (recombinant chimeric IgG1) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE). Binding of the ADC to CD30 on the cell surface initiates internalization of the MMAE-CD30 complex, followed by proteolytic cleavage that releases MMAE, leading to selective apoptosis of the Reed-Sternberg cells with minimal offtarget side effects, the major one being neuropathy. BV is approved for the treatment of adult patients with relapsed or refractory HL where ASCT failed as well as part of a maintenance or consolidation strategy post-asct for high-risk patients, which will also be discussed here. 25,26 Given that remission status pre-asct is highly predictive of outcome, the incorporation of BV with its favorable toxicity profile into an ST regimen is appealing. As a single agent in heavily pretreated patients, the PET-negative rate after 2 to 4 doses of BV is 30% to 40%. Two strategies have evolved to study this agent as part of ST: sequential administration of BV with chemotherapy and combined chemo-immunotherapy. The MSKCC and the City of Hope (COH) lymphoma groups reported on the sequential approach. 27,28 The designs of the studies were similar, with the primary difference being the BV dosing schedule. In the MSKCC trial, patients received 6 weekly doses of 332 American Society of Hematology

3 POST-ASCT BV consolidation Before 2015, there were only 2 phase 3 studies published for patients with relapsed HL. 32,33 Each study confirmed that ASCT was superior to ST alone; nearly all patients had relapsed as opposed to primary refractory disease. Little progress has been made in the past 2 decades except for decreased ASCT treatment related mortality, which is secondary to improved supportive care. Unfortunately, PFS remains at 50% if data are analyzed by intent-to-treat. Figure 2. Deauville 1-3 considered negative, P BV at 1.2 mg/kg; patients at COH were given 2 to 4 doses of an every-three-week dosing at 1.8 mg/kg. Patients in both studies with a PET-negative response went directly to HDT/ASCT, and additional ST was avoided; if PET-avid disease was persistent, then additional ST was given. The CR rate to BV alone was 30% to 40%, but this rate improved to 80% with the sequential programs. Consistent with previous data, the PET-negative patients had.75% 3-year PFS post-asct (Figures 2 and 3). There was no difference in outcome for patients only receiving BV compared with those requiring sequential therapy to achieve a CR. This approach is very appealing because some patients were able to avoid additional cytotoxic ST. However, predicting which of these patients will achieve CR is difficult. Our approach is to offer BV as initial therapy for patients with nodal-only disease. 29 At ASH in 2015, 2 very different chemo-immunotherapy ST programs were presented. The first, an outpatient regimen, combined BV with bendamustine. LaCasce et al reported preliminary data from a phase 1/2 study evaluating the safety and efficacy of these 2 agents as a ST program. 30 Fifty-five patients were treated; unexpectedly, there were severe infusion reactions seen in.50% of cycles, leading to an amendment and subsequent steroid premedications, which reduced this adverse event to become manageable. A PET-negative response was documented in 76% of patients; stem cell collection was adequate despite the concern of the known side effect of bendamustine on the bone marrow. Although the median follow-up is short at 18 months, 75% of patients are progression-free, making this outpatient ST appealing. In contrast, Garcia-Sanz et al reported data on 36 patients treated with an aggressive inpatient regimen: ESHAP1BV. 31 As expected, hematologic toxicity was significant. The CR rate in this ongoing clinical trial was reported at 83% with no stem cell mobilization failures. Both of these phase 2 studies are also administering post-asct BV as part of a consolidation strategy based on the results of the Aethera study, which will be described in the next section. Currently, the Seattle and HOVON groups are studying ICE1BV and DHAP1BV, respectively. Summary/Recommendation: The addition of BV to ST will increase the CR rate by 20%. However, the implication that all patients require this treatment is unclear. It seems reasonable for patients with low disease burden that single-agent BV should be initiated if available or chemotherapy alone if it is not. For patients with stage IV disease, chemo-immunotherapy or ST alone should be the initial treatment. In late 2010, the Aethera study was initiated. It was a phase 3, randomized, placebo-controlled trial that evaluated whether post- ASCT consolidation treatment with BV could prevent disease progression in patients with HL at high risk for relapse. 26 A consensus panel determined that primary refractory HL, initial remission duration of,1 year, or extranodal involvement constituted unfavorable risk; patients were required to have one of these factors for study eligibility. Aethera was written before the near-uniform agreement that an abnormal pre ASCT PET scan is the single most important factor in predicting outcome, and in fact the PET data that are available on study make recommendations for post-asct BV consolidation confusing. Patients were selected to randomly receive BV 1.8 mg/kg every 3 weeks or placebo for 16 cycles (~12 months), beginning 30 to 45 days after ASCT. Patients with progression of disease after ST were not eligible. Imaging studies were quarterly for the first year and then at 18 and 24 months during long-term follow-up (LTFU). Clinical lymphoma assessments were performed at each cycle of treatment, quarterly during the first year of LTFU, and every 6 months thereafter. A total of 329 patients were randomized to the BV (n 5 165) or placebo (n 5 164) treatment arms. Importantly, 60% of patients had primary refractory HL. Median PFS was not reached in the BV arm and was 15.8 months in the placebo arm; 3-year PFS rates were 61% and 43%, respectively (Figure 4). There were only 6 PFS events recorded after the 24-month evaluation, 3 in each cohort, and it is highly likely that patients in either arm at this time point are cured; there is currently no difference in OS. Administering 16 doses of BV does come with additional toxicity, namely neuropathy. Among the 112 patients in the BV arm with treatment-related peripheral neuropathy, 88% experienced improvement of symptoms at the time of 3-year analysis. Discontinuation of Figure 3. Complete response (CR) vs non-cr. Hematology

4 Figure 4. 3-year progression-free survival (PFS) data in the Aethera study. treatment because of any adverse events (AE) occurred in 54 patients (33%) in the BV arm, primarily as a result of neuropathy. Patients who discontinued treatment as a result of an AE received a median of 9.5 cycles (range, 1-15) in the BV arm. Interestingly, the 2-year PFS rate in these patients was 69% vs 82% for patients who completed all 16 treatment cycles. Five risk factors predicted for PFS on the Aethera study: initial remission duration,1 year,,cr to most recent salvage therapy, extranodal disease at the time of ST, B symptoms at the time of ST, and.1 ST required to achieve chemosensitive disease. It is clear from the data that patients who have at least 2 of these risk factors achieve benefit from consolidation (Figure 5). If one looks critically at the pre ASCT PET results, recommendations are fairly straightforward. Because a CR is a favorable risk factor, patients need at least 2 of 3 additional unfavorable risk factors (remission duration,1 year, extranodal disease or requiring.1 ST) for benefit to be achieved with BV consolidation. Summary/recommendations: Consolidation therapy improves PFS and it is reasonable to give a BV-naïve patient 1 year of post-asct therapy if he/she has at least 2 adverse risk factors. In patients who have previously received BV pre-asct and meet the risk factor requirements to be enrolled in Aethera, a patient should have achieved at least a partial response to BV-based treatment. In general, in this situation, which I suspect will become more frequent in the United States, I reduce the number of doses of BV post-asct to 10 or fewer. Treatment when ASCT fails: chronic HL vs reduced-intensity conditioning (RIC) allo-hct In 2009, when the Aethera study was written, the median OS of patients where ASCT failed was 30 months; in 2016, that number has doubled and will likely continue to increase. The reason is the robust drug development program in HL, specifically BV and the CPI. BV has been extensively discussed, but when given for palliation, OS improves by about 1 year. Other agents are also active, and results are summarized in Table 1. Historically, for patients where a good response was documented, a consult for an allo-hct ensued. These patients were given the option of transplant or palliation. The 1-year mortality from an allo-hct was 30%, with an equal number of patients being cured. This paradigm is clearly changing with the availability of the CPI. The role of allo-hct in HL is an area of great disagreement among lymphoma physicians. The case for chronic administration of CPI Targeting the PD-1/PDL1 pathway has revolutionized the way some of the common solid tumors are being treated. Studies are behind in the hematologic malignancies but are rapidly catching up. Recently the CPI, nivolumab, been approved for HL palliation and it is likely that pembrolizumab will also be approved. PDL1/2 is nearly uniformly expressed on Reed-Sternberg cells through chromosomal translocation, gene amplification, and EBV-related mechanisms. In HL, as well as primary mediastinal B-cell lymphoma, amplification of chromosome 9p23-4 is the most common genetic abnormality reported and the genes encoding PDL1 and 2 reside there; therefore, these 2 diseases are primed to respond to CPI American Society of Hematology

5 Figure 5. Risk factors associated with poor outcomes in the Aethera study. Both nivolumab and pembrolizumab are highly active, and phase 1 data were presented at ASH in 2014 and ,35 Results are quite similar with both agents, and treatment was administered for up to 2 years provided that the HL remained stable and/or the patient continued to have clinical benefit. These are unusual response criteria, and much different compared with traditional agents, when any time progression is documented, the study drug is discontinued. Because of this rule, PFS in these phase 1 studies are inflated. However, because clinical benefit included complete resolution of B symptoms, maintenance of palliative treatment was the correct choice, in my opinion. Beginning with Nivolumab, the dose is 3 mg/kg every 2 weeks and 23 patients with HL were treated. The patients were heavily pretreated with a median of 5 prior regimens received, but some were BV-naïve. The objective response rate was 87%, but only 5 patients achieved a CR based on PET criteria. Amazingly, 13 patients in CR or PR are no longer receiving treatment and the median PFS has not Table 1. New agents in HL Study Phase Drug Mechanism of action Route N ORR, N (%) CR PR SD Median PFS II Lenalidomide Immune Younes et al, II Panobinsotat Pan HDAC PO (27%) 5 (4%) 30 (23%) 71 (55%) 6.1 mo Batlevi et al, 2015 (in process) II Entinostat iso-spec HDAC PO 49 6 (12%) 0 (0%) 6 (12%) 6 (12%) 5.5 mo Ansell et al, I Nivolumab immune checkpoint IV (87%) 4 (17%) 16 (70%) 3 (13%) 86% at 24 wk Younes et al, II Brentuximab vedotin ADC IV (75%) 35 (34%) 41 (40%) 22 (22%) 5.6 mo Armand et al, 2015 Abstract 4 I Pembrolizumab Immune IV (66%) 5 (16%) 15 (48%) 7 (23%) Not reported checkpoint Johnston et al, 2010, II Everolimus MTOR inhibitor PO (42%) 5 (9%) 19 (33%) 20 (35%) 6 mo Abstract ,6 Fehniger et al, 2011 PO 38 7 (18%) 1 (3%) 6 (16%) 5 (13%) Not reported Abstract 7 modulator Hematology

6 Figure year PFS according to pre-allosct Deauville score. been reached. The 18-month OS was 83% and the majority of deaths were secondary to transplant-related morality in patients referred for an allo-hct. Patients enrolled in the study with pembrolizumab were eligible only if BV treatment failed. Patients received pembrolizumab at 10 mg/kg every 2 weeks. Thirty-one patients were enrolled. The CR and PR rates were 16% and 48%, respectively; 70% of the responses lasted longer than 24 weeks, with a median follow-up of 17 months. These phase 1 studies have led to large phase 2 clinical trials in which response rates were presented at ASCO and EHA this year. Eighty patients were included in the most recent published data for nivolumab; the CR and PR rates were 27% and 45%, respectively. Sixty patients were included in the most recent published data for pembrolizumab; 30 patients failed ASCT and BV, and 30 progressed on BV but were ASCT-ineligible. In the first cohort, the CR and PR rates were 20% and 50%, respectively, and 27% and 53%, respectively, in the second cohort. In both studies, most of the patients with demonstrable response continue to receive treatment. The side effect profiles of the CPI are different from traditional therapy and are usually immune-related. These include endocrinopathies such as thyroiditis, adrenal and pituitary dysfunction, hepatitis, colitis, and pneumonitis, which is of particular concern in patients with HL. Most of the patients treated with CPI with HL had previously received agents known to cause pulmonary dysfunction such as radiotherapy, bleomycin, gemcitabine, carmustine, and BV. I would caution administering a CPI when a patient has a history of pneumonitis requiring steroid support for symptom control. Summary/Recommendation: The CPI have been administered to patients with HL for the past 2 to 3 years and the OS of a patient with HL where ASCT failed has increased nearly the same amount. I will continue to use CPI liberally for palliation and keep patients on treatment until obvious disease progression ensues; however, a number of appealing clinical trials are underway combining CPI with other agents including BV and histone deacetylase (HDAC) inhibitors and, if available, I would recommend these options for my patients. Figure 7. Reasonable algorithm for RIC allo-hct. 336 American Society of Hematology

7 The case for RIC allo-hct The early studies of allo-hct in patients with HL were reported before the RIC era; OS was poor because of treatment-related mortality. 36 Therefore, most transplant physicians would agree that an ablative allo-hct is no longer a viable treatment option in HL. There is clear evidence of the graft-versus-lymphoma effect in HL based on 2 lines of evidence: graft-versus-host disease after allo-hct is associated with improved PFS and, second, donor lymphocyte infusions (DLI) as part of a T cell depleted strategy reduces the relapse rate. In 2016, with the availability of umbilical cord and haplo-identical transplants, nearly all patients will have a donor. 37 Therefore, if a patient is referred for RIC allo- HCT, this treatment will likely commence provided that the patient meets the standard criteria for an allo-hct, including some evidence of chemosensitive disease. However, it raises a critical question: which patients, and at what time should a patient be referred? To answer this question, one must consider the likelihood of cure after RIC. In 2016, registry data from the CIBMTR reported PFS and OS rates of only 20% and 37%, respectively, after a RIC for HL. If one evaluates RIC in the context of chemosensitive disease and performance status before transplant, the EBMT reported that 3-year PFS improved to 42% in favorable patients. We have data from MSKCC on 71 patients who underwent RIC for HL and reported that extranodal disease, less than CR at the time of RIC, and alemtuzumab-containing regimens were all associated with a poor outcome. 38 However, patients without any of these risk factors have a 3-year PFS approaching 60%. Confusing the matter further, data from the University of London where all the patients (n 5 116) were transplanted with a T cell depleted, alemtuzumabbased RIC, there was no difference in outcome in patients who had chemosensitive disease pretransplant based on PET status at the time of conditioning, with 3-year PFS rates of 59.4% and 55.7%, respectively, for PET-positive vs PET-negative response (Figure 6). 39 These data are helpful in the context of BV treatment asabridgetoric.inthepivotalphase2clinicaltrialleadingto US Food and Drug Administration approval of BV, 34 of 102 patients achieved a PET-negative response. 40 In addition, approximately one third of these CR patients have never relapsed. Therefore, patients achieving a CR to BV after a failed ASCT may benefit from BV treatment of up to 16 cycles and then can be monitored. Are the results better for RIC in patients who have not received a previous ASCT? There are no modern studies comparing ASCT vs RIC allo-hct. However, it is clear that there are subgroups of patients that have been described here that have,30% chance of being cured with ASCT. Summary/recommendation: A reasonable treatment paradigm is depicted in Figure 7. Conclusion A negative pre-asct PET scan is critical in the curative outcome of rel/ref HL and the incorporation of BV into ST can improve this metric. Post-ASCT consolidation with BV should be reserved for patients with multiple risk factors because the AEs are significant (namely, neuropathy). The checkpoint inhibitors are now the standard treatment of palliation and the question of how long these agents should be given before allo-hct demands prospective analysis. Correspondence Craig Moskowitz, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; moskowic@mskcc.org. References 1. Press OW, Li H, Schöder H, et al. US Intergroup Trial of Response- Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34(17): Engert A. ABVD or BEACOPP for Advanced Hodgkin Lymphoma. J Clin Oncol. 2016;34(11): Radford J, Illidge T, Barrington S. PET-Directed Therapy for Hodgkin s Lymphoma. N Engl J Med. 2015;373(4): Rancea M, von Tresckow B, Monsef I, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2014;92(1): Hoppe RT, Advani RH, Ai WZ, et al; National comprehensive cancer network. Hodgkin lymphoma, version J Natl Compr Canc Netw. 2015;13(5): Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin s lymphoma. N Engl J Med. 2015; 372(17): Perales MA, Ceberio I, Armand P, et al; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6): Josting A, Nogová L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7): Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin s lymphoma. J Clin Oncol. 2010; 28(34): Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3): Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23): Gentzler RD, Patel JD. Optimal first-line and maintenance treatments for advanced-stage nonsquamous non-small cell lung cancer. J Natl Compr Canc Netw. 2014;12(6): Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG- PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(11): Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol. 2016;95(5): Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7): Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Hematology

8 Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27): Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre- ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7): Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin s lymphoma. Haematologica. 2007;92(1): Sureda A, Arranz R, Iriondo A, et al; Grupo Español de Linformas/ Transplante Autólogo de Médula Osea Spanish Cooperative Group. Autologous stem-cell transplantation for Hodgkin s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/ Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5): Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant. 1997;20(1): Collins GP, Parker AN, Pocock C, et al; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol. 2014;164(1): Bröckelmann PJ, Müller H, Casasnovas O, et al. Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrhl). Blood. 2015;126: Shah GL, Bantilan KS, Verwys SL, et al. Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation. Blood. 2015;126: Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18Ffluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145(3): Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19): Moskowitz CH, Nademanee A, Masszi T, et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stemcell transplantation in patients with Hodgkin s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015;385(9980): Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin s lymphoma: a non-randomised, open-label, singlecentre, phase 2 study. Lancet Oncol. 2015;16(3): Chen R, Palmer JM, Martin P, et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12): Armand P, Shipp MA, Ribrag V, et al. PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. Blood. 2015;126: LaCasce AS, Bociek G, Sawas A, et al. Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 2015;126: Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood. 2015;126: Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852): Schmitz N, Pfistner B, Sextro M, et al; German Hodgkin s Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin s disease: a randomised trial. Lancet. 2002; 359(9323): Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016;34(23): Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin s lymphoma. N Engl J Med. 2015;372(4): Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3): Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin s lymphoma. J Clin Oncol. 2011;29(8): Barba P, Burns LJ, Litzow MR, et al; American Society for Blood and Marrow Transplantation Committee on Education. Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. Biol Blood Marrow Transplant. 2016;22(3): Reyal Y, Kayani I, Bloor AJ, et al. Impact of Pretransplantation (18)F- Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016;22(7): Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8): American Society of Hematology

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage

More information

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering

More information

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of

More information

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960

More information

Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma

Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed

More information

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing

More information

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)

More information

German Hodgkin Study Group

German Hodgkin Study Group German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of

More information

A CME-certified Oncology Exchange Program

A CME-certified Oncology Exchange Program A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett

More information

Does BV as part of salvage impact outcome?

Does BV as part of salvage impact outcome? Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College

More information

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction

More information

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle

More information

Practical Application of PET adapted Therapy in Hodgkin Lymphoma

Practical Application of PET adapted Therapy in Hodgkin Lymphoma Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Treatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center

Treatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop

More information

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust

Immune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint

More information

brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd

brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational

More information

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz

More information

AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital

AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure

More information

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John

More information

Confronto Real world e studi registrativi

Confronto Real world e studi registrativi Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY

More information

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies

More information

Brentuximab Vedotin in Lymphomas

Brentuximab Vedotin in Lymphomas New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000

More information

Hodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois

Hodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Introduction ORIGINAL PAPER. Med Oncol (2013) 30:611 DOI /s y

Introduction ORIGINAL PAPER. Med Oncol (2013) 30:611 DOI /s y Med Oncol (2013) 30:611 DOI 10.1007/s12032-013-0611-y ORIGINAL PAPER Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniformmodified BEAM-conditioning

More information

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy

More information

Hodgkin Lymphoma Nivolumab

Hodgkin Lymphoma Nivolumab New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells

More information

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era HODGKIN LYMPHOMA PROGNOSIS AND THERAPY Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era Solomon A. Graf 1,2 and Ajay K. Gopal 1,2 1 Department of Medicine and 2 Fred Hutchinson

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013

pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

CME Information LEARNING OBJECTIVES

CME Information LEARNING OBJECTIVES CME Information LEARNING OBJECTIVES Assess the efficacy and safety of brentuximab vedotin in investigational settings, such as in combination with AVD for patients with newly diagnosed HL, as consolidation

More information

Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist

Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune

More information

Alexander Fosså, M.D. PhD.

Alexander Fosså, M.D. PhD. Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: 8.01.29 Last Review: 1/2019 Origination: 4/2014 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar

More information

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma

The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Hospital Universitari Quirón Dexeus Barcelona, Spain 9 th Educational Course on Lymphomas

More information

Checkpoint Blockade in Hematology and Stem Cell Transplantation

Checkpoint Blockade in Hematology and Stem Cell Transplantation Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures

More information

New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic

New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy

More information

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion

More information

Response Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy

Response Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: 8.01.29 Last Review: 1/2018 Origination: 4/2014 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Hodgkin Lymphoma New Combo-Steps

Hodgkin Lymphoma New Combo-Steps New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:55-3:10 p.m Combinations with Immune Checkpoint

More information

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma Protocol Hematopoietic Cell Transplantation for Hodgkin Lymphoma (80129) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10, 01/11,

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab (Adcetris) for Hodgkin Lymphoma - Resubmission February 21, 2018

pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab (Adcetris) for Hodgkin Lymphoma - Resubmission February 21, 2018 pan-canadian Oncology Drug Review Final Clinical Guidance Report Brentuximab (Adcetris) for Hodgkin Lymphoma - Resubmission February 21, 2018 DISCLAIMER Not a Substitute for Professional Advice This report

More information

PET-imaging: when can it be used to direct lymphoma treatment?

PET-imaging: when can it be used to direct lymphoma treatment? PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict

More information

Welcome and Introductions

Welcome and Introductions Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016

More information

Radiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin

Radiation therapy has a dramatic effect on lymphomas, and has played an important role in treating Hodgkin COUNTERPOINTS Current Controversies in Hematology and Oncology Can Radiotherapy Be Omitted in Patients With Localized Hodgkin Lymphoma? Radiation therapy has a dramatic effect on lymphomas, and has played

More information

First line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented

First line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented [Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,

More information

Presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA

Presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA 65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas

More information

Jonathan W Friedberg, MD, MMSc

Jonathan W Friedberg, MD, MMSc I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer

More information

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital

More information

Brentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase

Brentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Medical Policy Manual Transplant, Policy No. 45.30 Hematopoietic Cell Transplantation for Hodgkin Lymphoma Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER

More information

Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma

Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma Presented as a Live Webinar Thursday, October 26, 2017 1:00 2:00 p.m. ET On-demand Activity Live webinar recorded and archived to be

More information

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Protocol. Hematopoietic Cell Transplantation for Hodgkin Lymphoma Protocol Hematopoietic Cell Transplantation for Hodgkin Lymphoma (80129) (Formerly Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma) Medical Benefit Effective Date: 04/01/18 Next Review Date:

More information

Dr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK

Dr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: Original Effective Date: MM.07.015 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 05/26/2017 Section: Transplants

More information

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center

Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many

More information

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin s Lymphoma (HL) in the ABVD Therapeutic Era

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin s Lymphoma (HL) in the ABVD Therapeutic Era Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin s Lymphoma (HL) in the ABVD Therapeutic Era Sarah F. Keller, 1 Jennifer L. Kelly, 1 Elizabeth Sensenig, 2 Jennifer

More information

Multiple Myeloma Updates 2007

Multiple Myeloma Updates 2007 Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from

More information

Outcomes of Hodgkin s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation

Outcomes of Hodgkin s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation Outcomes of Hodgkin s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation Panayotis Kaloyannidis, 1 Georgia Voutiadou, 1 Ioannis Baltadakis, 2 Panagiotis

More information

Medical Benefit Effective Date: 04/01/12 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 01/10, 01/11, 01/12

Medical Benefit Effective Date: 04/01/12 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 01/10, 01/11, 01/12 Protocol Hematopoietic Stem-Cell Transplantation for Hodgkin Lymphoma (80129) Medical Benefit Effective Date: 04/01/12 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 01/10, 01/11,

More information

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin s lymphoma autografted after a first relapse

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin s lymphoma autografted after a first relapse Original article Annals of Oncology 16: 625 633, 2005 doi:10.1093/annonc/mdi119 Published online 28 February 2005 Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin

More information

Nivolumab in Hodgkin Lymphoma

Nivolumab in Hodgkin Lymphoma Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle

More information

Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath

Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain

More information

CAR-T cell therapy pros and cons

CAR-T cell therapy pros and cons CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research

More information

pan-canadian Oncology Drug Review Final Economic Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 pan-canadian Oncology Drug Review Final Economic Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

Published Ahead of Print on April 2, 2009 as /theoncologist Salvage Therapy in Hodgkin s Lymphoma

Published Ahead of Print on April 2, 2009 as /theoncologist Salvage Therapy in Hodgkin s Lymphoma The Oncologist Lymphoma Salvage Therapy in Hodgkin s Lymphoma JASON H. MENDLER,JONATHAN W. FRIEDBERG James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA Key

More information

First Line Management of Classical Hodgkin Lymphoma

First Line Management of Classical Hodgkin Lymphoma First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /

More information

Lymphoma- Med A-new drugs and treatments

Lymphoma- Med A-new drugs and treatments Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is

More information

Published Ahead of Print on April 3, 2015, as doi: /haematol Copyright 2015 Ferrata Storti Foundation.

Published Ahead of Print on April 3, 2015, as doi: /haematol Copyright 2015 Ferrata Storti Foundation. Published Ahead of Print on April 3, 2015, as doi:10.3324/haematol.2015.124784. Copyright 2015 Ferrata Storti Foundation. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital

NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification

More information

Ferrata Storti Foundation

Ferrata Storti Foundation ARTICLES Introduction Hodgkin s Lymphoma Brentuximab vedotin in relapsed/refractory Hodgkin s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia

More information

Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD

Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific

More information

Hematopoietic Cell Transplantation for Hodgkin Lymphoma

Hematopoietic Cell Transplantation for Hodgkin Lymphoma Hematopoietic Cell Transplantation for Hodgkin Lymphoma Policy Number: Original Effective Date: MM.07.015 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 4/27/2018 Section: Transplants

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

Hodgkin. The PET World. Sally Barrington

Hodgkin. The PET World. Sally Barrington Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging

More information

Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX

Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX Best of ASCO 2011 Lymphoma Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX RCHOP21 in DLBCL (GELA LNH-98.5 Study) Survival Probability OS (N = 399)

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy INDICATIONS FOR USE: INDICATION Brentuximab Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or Following at least two

More information

Department of Internal Medicine, Division of Oncology/Hematology, Nebraska Medical Center, Omaha, NE 68198, USA

Department of Internal Medicine, Division of Oncology/Hematology, Nebraska Medical Center, Omaha, NE 68198, USA Open Journal of Clinical & Medical Case Reports Volume 4 (2018) Issue 2 ISSN 2379-1039 Autologous hematopoietic stem cell transplantation in a patient with Hodgkin lymphoma on dialysis: Use of brentuximab

More information

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas

More information

Advanced stage HL The old and new match: BEACOPP

Advanced stage HL The old and new match: BEACOPP 27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment

More information

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and

More information

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Peter W. M. Johnson Cancer Research UK Centre, University of

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all

What is the best approach to the initial therapy of PTCL? standards of treatment? Should all What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital

More information

Immunotherapy on the Horizon

Immunotherapy on the Horizon Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2

More information

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of

More information

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following

More information

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France

More information

AGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM

AGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies

More information

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Cell Transplantation for Hodgkin Lymphoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_hodgkin_lymphoma

More information